NYSE:GNRC
NYSE:GNRCElectrical

Is Generac Stock Attractively Priced After Data Center and Grid Resiliency Tailwinds in 2025?

If you are wondering whether Generac Holdings is quietly trading below what it is really worth, you are not alone. This article is going to unpack exactly that. The stock has been choppy, up 0.6% over the last week and 2.2% over the past month, but still down 6.8% over the last year and 27.4% over five years, even after a strong 58.3% gain over three years. Recent headlines have focused on Generac’s role in backing up power for data centers, growing grid instability, and the rising adoption...
NYSE:GOLD
NYSE:GOLDRetail Distributors

Should Gold.com’s (GOLD) High-Profile Rebrand Meaningfully Change How Investors View Its Core Business?

Earlier this month, A-Mark Precious Metals, Inc. officially changed its corporate name to Gold.com, Inc. and, effective December 3, 2025, switched its New York Stock Exchange ticker symbol from AMRK to GOLD, accompanied by bylaw updates to reflect the rebranding. This shift to the highly recognizable Gold.com brand and GOLD ticker may reshape how investors perceive the company’s role in the precious metals market and its future business direction. We’ll now consider how the rebrand to...
NYSE:CHE
NYSE:CHEHealthcare

Chemed (CHE): Evaluating Valuation After This Year’s Double-Digit Share Price Slide

Chemed (CHE) has quietly slid this year, even as its underlying hospice and plumbing businesses keep growing. That disconnect between share price and fundamentals is what makes the stock interesting right now. See our latest analysis for Chemed. The share price has drifted lower this year, with a roughly 20 percent year to date share price decline and a similar double digit drop in one year total shareholder return. This suggests sentiment is fading even as earnings keep grinding higher. If...
TSE:5201
TSE:5201Building

How AGC’s ATUM Partnership and Leadership Shuffle Could Shape AGC (TSE:5201) Life Science Ambitions

On December 9, 2025, AGC Inc. held a board meeting to approve changes to its Board of Directors, Audit & Supervisory Board, and Executive Officers, while AGC Biologics earlier partnered with ATUM to integrate the Leap-In Transposase expression platform into its global Cell Line Development Center of Excellence. This collaboration adds a modern transposase-based system alongside AGC Biologics’ CHEF1 Expression Technology, aiming to shorten drug developers’ timelines and broaden the company’s...
NasdaqGS:AMPH
NasdaqGS:AMPHPharmaceuticals

Is Amphastar Pharmaceuticals Mispriced After a Tough Year and Promising Cash Flow Outlook in 2025?

Wondering if Amphastar Pharmaceuticals is a bargain after its rough patch, or if the market sees something you do not? Let us unpack what the current share price might really be telling you about its long term value. The stock has slipped 3.8% over the last 7 days, but it is up 6.7% over the past month and still down 29.5% year to date and 41.2% over the last year. This profile hints at both recovery potential and lingering skepticism. Recent headlines around Amphastar have focused on its...
NYSE:EOG
NYSE:EOGOil and Gas

Is EOG Resources Mispriced After 2025 Share Price Slide And Strong DCF Upside?

Wondering if EOG Resources at around $109 is a bargain or a value trap right now? You are not alone, and this breakdown will help you see where the market might be mispricing it. The stock has slipped 1.9% over the last week and is still down 12.3% year to date and 11.3% over the past year, even after a strong 164.2% gain over five years, which hints at shifting sentiment around its long term prospects and risk. Recent headlines have focused on EOG tightening its capital discipline,...
NasdaqGS:HSIC
NasdaqGS:HSICHealthcare

Is Henry Schein’s Streamlined Distribution Strategy Creating Value at Around $74 a Share in 2025?

Wondering if Henry Schein at around $74 a share is a quietly undervalued play in healthcare rather than a sleepy distributor? That is exactly what we are going to unpack here. The stock has crept up about 2.1% over the last week and 2.0% over the past month, and is up 8.6% year to date, even though the 1 year return is still slightly negative at around 3.1% and the 3 year return sits near 10.5% in the red. Recent headlines have focused on Henry Schein sharpening its focus on dental and...
NasdaqGM:CRML
NasdaqGM:CRMLMetals and Mining

Critical Metals (CRML) Is Up 24.8% After Sealing EU Rare Earth Processing JV - What's Changed

Critical Metals Corp. recently signed a 50/50 term-sheet joint venture with Romania’s state-owned FPCU to develop and operate a rare earth processing plant, creating what is described as Europe’s first fully integrated mine-to-processing rare earth supply chain. By committing half of the Tanbreez Project’s rare earth concentrates to this Romanian plant for the life of the mine, the deal directly targets Europe’s long-standing dependence on Chinese rare earth processing for industrial and...
OB:WAWI
OB:WAWIShipping

Why Wallenius Wilhelmsen (OB:WAWI) Is Up 11.6% After Extending Emissions-Linked European Shipping Contracts

Wallenius Wilhelmsen recently extended two major shipping contracts, adding close to US$500 million in estimated value through longer terms, extra volumes, wider trade lanes, and multi-fuel bunker adjustment mechanisms tied to emission reductions. These renewals with a premium European auto maker and a leading heavy equipment producer reinforce the company’s role as a long-term logistics partner for core European manufacturing supply chains. We’ll now examine how these extended,...
NYSE:SXT
NYSE:SXTChemicals

Sensient Technologies (SXT): Revisiting Valuation After a Strong Year-to-Date Share Price Run

Sensient Technologies (SXT) has been quietly grinding higher this year, and with the stock now around 93 dollars after a strong year to date run, investors are revisiting its valuation. See our latest analysis for Sensient Technologies. That move to about 92.66 dollars caps a strong run, with the share price delivering a 32.5 percent year to date return while the three year total shareholder return of 33.69 percent suggests momentum has been rebuilding after a softer patch. If Sensient’s...
NYSE:UGI
NYSE:UGIGas Utilities

UGI (UGI): Reassessing Valuation After a Strong Year-to-Date Share Price Rally

UGI has been quietly grinding higher this year, and that steady climb is starting to catch more investor attention. With shares up roughly 33% year to date, the stock’s move invites a closer look. See our latest analysis for UGI. The recent 10.3% 1 month share price return, on top of a 33.5% year to date share price gain and a 38.0% 1 year total shareholder return, suggests momentum is building as investors reassess UGI’s earnings resilience and valuation. If UGI’s steady climb has you...
NYSE:MC
NYSE:MCCapital Markets

Moelis (MC) Is Up 6.7% After Winning Netflix–Warner Bros. Mandate Amid Brighter M&A Outlook

In recent days, Morgan Stanley highlighted Moelis & Company in a positive sector outlook, suggesting advisory firms could benefit from an earlier-than-expected rebound in sponsor-led transactions and related capital markets activity. This supportive industry view arrives soon after Moelis was appointed financial advisor to Netflix on its US$82.70 billion bid for Warner Bros., a high-profile mandate that underscores the firm’s standing in large-scale M&A advisory. With this backdrop, we’ll...